Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6AVO

Cryo-EM structure of human immunoproteasome with a novel noncompetitive inhibitor that selectively inhibits activated lymphocytes

6AVO の概要
エントリーDOI10.2210/pdb6avo/pdb
EMDBエントリー7010
分子名称Proteasome subunit beta type-9, Proteasome subunit alpha type-2, Proteasome subunit beta type-1, ... (15 entities in total)
機能のキーワードinhibitor, complex, immunoproteasome, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数28
化学式量合計716690.06
構造登録者
Li, H.,Santos, R.,Bai, L. (登録日: 2017-09-04, 公開日: 2017-12-06, 最終更新日: 2025-05-28)
主引用文献Santos, R.L.A.,Bai, L.,Singh, P.K.,Murakami, N.,Fan, H.,Zhan, W.,Zhu, Y.,Jiang, X.,Zhang, K.,Assker, J.P.,Nathan, C.F.,Li, H.,Azzi, J.,Lin, G.
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.
Nat Commun, 8:1692-1692, 2017
Cited by
PubMed Abstract: Proteasome inhibitors benefit patients with multiple myeloma and B cell-dependent autoimmune disorders but exert toxicity from inhibition of proteasomes in other cells. Toxicity should be minimized by reversible inhibition of the immunoproteasome β5i subunit while sparing the constitutive β5c subunit. Here we report β5i-selective inhibition by asparagine-ethylenediamine (AsnEDA)-based compounds and present the high-resolution cryo-EM structural analysis of the human immunoproteasome. Despite inhibiting noncompetitively, an AsnEDA inhibitor binds the active site. Hydrophobic interactions are accompanied by hydrogen bonding with β5i and β6 subunits. The inhibitors are far more cytotoxic for myeloma and lymphoma cell lines than for hepatocarcinoma or non-activated lymphocytes. They block human B-cell proliferation and promote apoptotic cell death selectively in antibody-secreting B cells, and to a lesser extent in activated human T cells. Reversible, β5i-selective inhibitors may be useful for treatment of diseases involving activated or neoplastic B cells or activated T cells.
PubMed: 29167449
DOI: 10.1038/s41467-017-01760-5
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.8 Å)
構造検証レポート
Validation report summary of 6avo
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon